Newborn screening for neuroblastoma

Current Opinion in Pediatrics

Volumn 9, Issue 1, 1997, Pages 70-73

  Parker, Louise ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOVANILLIC ACID; VANILMANDELIC ACID;

CANCER REGISTRY; EUROPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCIDENCE; JAPAN; MASS SCREENING; MORTALITY; NEUROBLASTOMA; NEWBORN SCREENING; NORTH AMERICA; PRIORITY JOURNAL; REVIEW;

EID: 0030939858     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199702000-00014     Document Type: Review

References (27)

1. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW: Prognostic factors in neuroblastoma. Cancer 1987, 59:1853-1859.
2. Evans AE, August CS, Kamani N, Bunin N, Goldwein J, Ross AJ III, DUAngio GJ: Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital in Philadelphia: an update. Med Pediatr Oncol 1994, 23:323-327.
3. Pritchard J, Barnes J, Germond S, Hartman O, De Kraker J, Lewis I, Lockwood L, Wallendszus K: Stage and urinary catecholamine metabolite excretion in neuroblastoma. Lancet 1989, 2:514-515.
4. Tuchman M, Ramnaraine MLR, Woods WG, Krivit W: Three years of experience with random urinary homocanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987, 79:203-205.
5. Sawada T, Todo S, Fujita K, Lino S, Imashuka S, Kusunoki T: Mass screening of neuroblastoma in infancy. Am J Dis Child 1982, 136:710-712.
6. Nishi M, Miyake H, Takeda T, Schimada M: Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987, 60:433-436.
7. Parker L, Craft AW, Dale G, Bell S, Mole M, McGill AC, Seviour JA, Smith J: Screening for neuroblastoma in the North of England. BMJ 1992, 305:1260-1263.
8. Woods WG, Tuchman M, Bernstein ML, LeClero J, Brisson L, Look T, Brodeur GM, Shimada H, Hann HL, Robinson LL, Shuster JJ, Lemieux B: Screening for neuroblastoma in North America. Am J Pediatr Hematol Oncol 1992, 14:312-319.
9. Schilling FH, Erttman R, Dohrmann S, Erb N, Winkler, Gross U, Treuner J: Early neuroblastoma selection in Germany: on the status of the Hamburg-Stuttgart Cooperative Pilot Study. Klin Padiatr 1992, 204:282-287.
10. Berthold F, Sander J, Baillot A, Hunneman DH, Michaelis J: Neuroblastomscreening-Projekt Niedersachsen/Nordrhein-Westfalen: Zur Notwendigkeit des Epidemiologischen Verleichs. Klin Padiatr 1992, 204:288-292.
11. Mathieu P, Favrol M, Frappax D, Chauvin F, Greffe J, Montegue A, Lacrois C, David L, Brunet-Mentigny M, Philip T: Neuroblastoma in children: clinical and biological aspects. An experience of screening in France. Ann Biol Clin (Paris) 1993, 51:665-668.
12. Kerbl R, Urban C, Starz I, Ambros IM, Strehl S, Kovar H, Gadner H, Ambros PP: Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life. Med Pediatr Oncol 1993, 21:625-626.
13. Bayliss U, Wiley VC, Wilcken B: Neuroblastoma screening in New South Wales. In 3rd International Symposium on Neuroblastoma Screening. Kyoto: Kyoto Foundation for the Promotion of Medical Sciences; 1993.
14. Yamamoto K, Hayashi Y, Hanada R, Kikuchi A, Ichikawa M, Tanimur M, Yoshioka S: Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995, 13:2033-2038. This report shows a big increase in the incidence of neuroblastoma following the introduction of screening without a concomitant fall in cases in older children.
15. Asami T, Otabe N, Wakabayshi M, Kakihara T, Uchiyama M, Asami K: Screening for neuroblastoma: 9-year birth cohort-based in Niigata, Japan. Acta Paediatr 1995, 84:1173-1176. This report of the incidence and mortality presented by birth cohort is especially useful. Analysis shows the increase in incidence and in another 4 or 5 years time will give useful information on mortality rates.
16. Hanawa Y, Sawada T, Tsunoda A: Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 1990, 18:472-475.
17. Cole M, Parker L, Craft AW: Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 1992, 20:84-85.
18. Nishi M, Takeda T, Hanai J, Kikuchi Y: Mass screening for neuroblastoma and mortality in birth cohorts. In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995. Abstract of presentation by one of the first screening groups in Japan. Mortality is falling in Japan, but is it due to screening?
19. Tuchman M, Lemieux B, Robison LL, Leclerc J-M, Bernstein M, Brisson L, Brossard J, Hill G, Shuster J, Byrne T, Bunin G, Woods WG: Screening for neuroblastoma (NB) increases the overall incidence of the disease without reducing the incidence of advanced stage NB. In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995. Important results showing increased incidence of neuroblastoma from the North American study without reduction in later-stage disease or disease in older children.
20. Yamamoto K, Hanad R, Kikuchi A, Ichiawa M, Tsukamoto K, Aihara T: Six cases with neuroblastoma detected by mass screening and followed-up without treatment. In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995. Six children with apparent neuroblastoma detected by screening were followed up until their urinary catecholamine metabolites returned to normal and their tumors disappeared.
21. Takeuchi LA, Hachitanda Y, Wood WG, Tuchman M, Lamiex B, Brisson L, Bernstein M, Brossard J, Leclerc J, Byrne TD, et al.: Screening for neuroblastoma in North America: preliminary results of a pathology review from the Quebec project. Cancer 1995, 76:2363-2371. More results of the North American screening study, showing that the majority of children detected by screening have disease of favorable pathology.
22. Hachitanda Y, Monobe Y, Takeuchi LA, et al.: Histopathology of neuroblastomas detected and not-detected through mass screening program: a report from the Quebec Project. In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995. Children who were missed by the screening program in North America were much more likely to have disease with unfavorable characteristics than those detected by screening.
23. Woods WG, Tuchman M, Brodeur GM, Leclerc JM, Bernstein M, Brisson L, Brossard J, Look T, Shimada H, Byrne T, Lemieux B: Clinical and biologic parameters from patients (PTS) diagnosed with neuroblastoma as part of the Quebec Screening Project (QNSP): differences between cases detected by screening and those diagnosed clinically. In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995.
24. Tafese T, Erttman R, Berthold F, Kerbl R, Mann J, Parker L, Schilling F, Philip T: Clinical and biological presentation of 47 neuroblastoma detected by the Study group for Evaluation of Neuroblastoma Screening in Europe (SENSE). In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995. Report on the screening projects in United Kingdom, France, Germany, and Austria. Overall detection rate was 1 in 4000, indicating that over diagnosis occurred.
25. Sawada T, Shikata T, Matsumuna T, Kawakatsu H, Sugimoto T, for the Neuroblastoma Screening Study Group: Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infant Japan. Prog Clin Biol Res 1994, 385:371-375.
26. Esteve J, Parker L, Roy P, Herrmann F, Duffy S, Frappaz D, Lasset C, Hill C, Sancho-Garnier H, Michaelis J, Phillip T: Is there a need for the evaluation of neuroblastoma screening: would it be feasible? Br J Cancer 1995, 7:1125-1131. Statistical estimation of the likely effects of screening for neuroblastoma.
27. Schilling FH, Berthold F, Erttmann R, Sander J, Treuner J: An epidemiological study to evaluate neuroblastoma screening at 12 months of age in Germany. In 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany: Olgahospital Stuttgart; 1995. The first report of the large German study in which 1.25 million children will be screened.